Replies to post #22122 on Cytodyn Inc (CYDY)

[ADVFN_greedfear]

I'm sure I could not have done better. I would have done worse. But that's not the issue. The question remains why a company with multi billion dollar revenues potential in advanced clinical trials (showing good results as far as we know) is struggling for a fair valuation. Who is to "blame" for that? There can only be one answer and it's not the shareholders or the market.

[weasel6667]

It seems it is absolute forbidden to say anything in the slightest way negative on this board about the management, it seems like they are somehow holy for some individuals here. Nobody said that they did anything wrong in the trial or in the medical field, there was no criticism in this direction.
Fact is, the SP matters and has mattered especially in connection with the private placements. The ragged mistakes (e.g. reverse split story) of the management leaded and leads to avoidable additional dilution over time. Or was this ragged reverse split nonsense also due to some top secret FDA rules? To explain or defend most management mistakes by the evil FDA gets slowly worn out.
Mistakes happen and nobody is perfect. No problem with that. But if there are too many mistakes in a row, it must be allowed to articulate and question that.

When somebody on this board says "SP does not matter for management" then this is nonsense. => Yeah lets have the next private placements at 20cents or 10cents ... who cares ...